Browsing Tag
rhenium-186
3 posts
What manufacturing scale-up means for REYOBIQ’s regulatory and clinical trajectory
Explore how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing and what it means for regulatory approval and clinical success.
Can Moleculin Biotech, Inc. translate preclinical pancreatic cancer signals into clinical impact?
Explore how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing and what it means for regulatory approval and clinical success.
Investors eye Plus Therapeutics after promising ReSPECT-LM results and FDA fast-track push for REYOBIQ in brain metastases
See how Plus Therapeutics’ REYOBIQ delivered >75 percent benefit and no toxicity in its ReSPECT-LM trial—discover what this means for CNS cancer treatment and investors.